Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Freshara Agro Exports Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
New production unit capacity utilization to improve from current 60% to 70-80% in next few months, supporting volume growth. Key concall takeaways from…
3 Aug 2026
RNFI Services Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Recent fundraising: Paysprint raised INR10 crore at a INR120 crore valuation, with RNFI’s stake reducing from 60% to 55%. Key concall takeaways from RNFI…
3 Aug 2026
Stallion India Fluorochemicals Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Manufacturing expansion supported by phased CapEx and capital market funding, enabling accelerated growth and improved EBITDA margins possibly near 30% at…
3 Aug 2026
OSEL Devices Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
3 Aug 2026
Laxmi Dental Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Scanner sales growth to continue, with digital penetration in India planned to increase from 79% to 90%, driving future expansion. Key concall takeaways from…
3 Aug 2026
Laxmi Dental Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
68 crores over two years planned to support expansion. Key concall takeaways from Laxmi Dental Ltd's Q1 FY26 earnings call — and how it ranks against sector…
3 Aug 2026
Suraksha Diagnostic Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Stable revenue mix between pathology (around 54-56%) and radiology (44-45%), consistent over the last 2-3 years. Key concall takeaways from Suraksha Diagnostic…
3 Aug 2026
Western Carriers (India) Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Quarter-on-quarter revenue grew approximately 9% in Q3 FY’26, indicating consistent upward momentum. Key concall takeaways from Western Carriers (India) Ltd's…
3 Aug 2026
Arkade Developers Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
8,000 crores. Key concall takeaways from Arkade Developers Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
3 Aug 2026
Ecos (India) Mobility & Hospitality Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Existing customers demonstrated a 23% growth, contributing significantly to revenue increases. Key concall takeaways from Ecos (India) Mobility & Hospitality…
3 Aug 2026
Orient Technologies Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
H1 FY26 revenue grew 30.48% YoY, indicating strong growth momentum. Key concall takeaways from Orient Technologies Ltd's Q2 FY26 earnings call — and how it…
3 Aug 2026
Medicamen Organics Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
The company plans a 60% CAGR in revenue over the next three years. Key concall takeaways from Medicamen Organics Ltd's Q4 FY25 earnings call — and how it ranks…
3 Aug 2026
Megatherm Induction Q2 FY26: Order Book ₹430 Cr | Arthneeti
Q2 FY26
Current capacity supports around ₹450-500 crore; further ₹25-30 crore CapEx planned to reach ₹950-1,000 crore. Key concall takeaways from Megatherm Induction…
3 Aug 2026
GPT Healthcare Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Base business growth excluding new hospitals like Raipur is around 6%-6.5%, on track with previous commitments (Page 6). Key concall takeaways from GPT…
3 Aug 2026
Shanti Gold International Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Initial production at Jaipur plant to be 300 kgs, scaling up to 100% capacity by year-end. Key concall takeaways from Shanti Gold International Ltd's Q2 FY26…
3 Aug 2026
Influx Healthtech Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Capacity utilization is currently increasing (nutraceuticals ~65%-70%), with further expansion aligned with order flows to sustain growth. Key concall…
3 Aug 2026
Arisinfra Solutions Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Contract manufacturing capacity is currently about 9 million metric tons with utilization increasing from 45% to over 55%, indicating potential for significant…
3 Aug 2026
Indo Farm Equipment Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
60 to 70 crore. Key concall takeaways from Indo Farm Equipment Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
3 Aug 2026
Suraj Estate Developers Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Collections showed robust growth (INR115 crores in Q1 FY '26 vs INR72 crores in Q1 FY '25), indicating strong execution and customer cash flow. Key concall…
3 Aug 2026
P I Industries Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
New product portfolio continues to grow (~10% growth in new products for 9 months FY26), supporting de-risking strategy. Key concall takeaways from P I…
3 Aug 2026